The Swallowing Side Effects of Botulinum Toxin Type A Injection in Spasmodic Dysphonia

1996 ◽  
Vol 106 (1) ◽  
pp. 86-92 ◽  
Author(s):  
Susan E. Sedory Holzer ◽  
Christy L. Ludlow
1996 ◽  
Vol 106 (3) ◽  
pp. 296-300 ◽  
Author(s):  
Scott G. Adams ◽  
Lisa C. Durkin ◽  
Jonathan C. Irish ◽  
David L.H. Wong ◽  
Elizabeth J. Hunt

1996 ◽  
Vol 39 (5) ◽  
pp. 968-980 ◽  
Author(s):  
Kimberly V. Fisher ◽  
Ronald C. Scherer ◽  
Chwen G. Guo ◽  
Ann S. Owen

Following Botulinum Toxin Type A injection, glottal competency of an adductor spasmodic dysphonia patient is thought to vary over a wide range. This study quantifies variability in laryngeal adduction for one such patient over a 10-week period. Analyses of kinematic and aerodynamic measures were used to track the voice weekly. The measures included the electroglottographic waveform width (EGGW50), nondimensional electroglottographic slope quotient (SLQ), glottal flow open quotient (FOQ), dc glottal flow, and nondimensional glottal flow peak quotient (FPQ). The results suggested that change in degree of glottal adduction over time can be observed even when vocal instability is present within each recording session. Perceptual ratings of vocal quality (breathy to pressed) were related to the laryngeal measures. The coefficient of variation for EGGW50 and the percentage of dichrotic phonations reached minima during sessions with predominantly breathy and hypoadducted phonation. The methods used in this study show potential to aid decisions about dose level and sources of perceptual adductor spasmodic dysphonia symptoms for a given patient.


2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Stefano Scamoni ◽  
Luigi Valdatta ◽  
Claudia Frigo ◽  
Francesca Maggiulli ◽  
Mario Cherubino

Background. Local injections of Botulinum toxin type A (BTX-A) are an effective and safe solution for primary bilateral axillary hyperhidrosis. Traditional treatments are often ineffective and difficult to tolerate. This study was performed to assess the efficacy and safety of Botulinum toxin type A in the treatment of these diseases and to evaluate the reliability of patient’s subjective rating in the timing of repeat injections. Methods. From 2007 to 2008, we included in the study and treated a total of 50 patients, and we used the Minor’s iodine test and the hyperhidrosis diseases severity scale as initial inclusion criteria and also for evaluating the followup, comparing to patient’s subjective rating. We used also a specific questionnaire to evaluate the level of pain, the onset of the effect, any eventual adverse effect of the treatment, the onset of compensatory hyperhidrosis, and the global grade of satisfaction. The data were analyzed using standard statistical methods. Results. 88% of patients were totally satisfied and all patients repeated the treatment during all the study. The symptom-free interval was in median 6 months with an average improving of HDSS of 1.5 points. In 86%, there was a complete accordance between the subjective patient’s demand of the repetition of the treatment and the positivity to Minor test and HDSS. No major side effects happened. Conclusion. Local injections of Botulinum toxin type A (BTX-A) result in an effective and safe solution for bilateral axillary primary hyperhidrosis for the absence of significant morbidity, side effects, and lack of efficacy or duration. The only defects are the need of repetition of the treatment and relative costs.


1996 ◽  
Vol 106 (12) ◽  
pp. 1476-1481 ◽  
Author(s):  
Michael J. Koriwchak ◽  
James L. Netterville ◽  
Todd Snowden ◽  
Mark Courey ◽  
Robert H. Ossoff

2017 ◽  
Vol 31 (3) ◽  
pp. 378.e19-378.e24 ◽  
Author(s):  
Wonjae Cha ◽  
Jeon Yeob Jang ◽  
Soo-Geun Wang ◽  
Ji-Heon Kang ◽  
Min-Gyu Jo

1994 ◽  
Vol 104 (6) ◽  
pp. 656???662 ◽  
Author(s):  
Paul F. Castellanos ◽  
George A. Gates ◽  
Gregory Esselman ◽  
Felix Song ◽  
Michael W. Vannier ◽  
...  

2011 ◽  
Vol 86 (1) ◽  
pp. 68-72 ◽  
Author(s):  
Ricarda M. Bauer ◽  
Christian Gratzke ◽  
Alexander Roosen ◽  
Yasmin Hocaoglu ◽  
Margit E. Mayer ◽  
...  

2017 ◽  
Vol 75 (2) ◽  
pp. 87-91 ◽  
Author(s):  
Jean Pierre Mette Batisti ◽  
Alais Daiane Fadini Kleinfelder ◽  
Natália Bassalobre Galli ◽  
Adriana Moro ◽  
Renato Puppi Munhoz ◽  
...  

ABSTRACT Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary tonic or clonic contractions of the muscles innervated by the facial nerve. Objective To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of HFS. Methods A retrospective analysis of patients treated at the Movement Disorders Outpatient Clinic in the Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, from 2009 to 2013 was carried out. A total of 550 BTX-A injections were administered to 100 HFS patients. Results Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%). Conclusion Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.


Sign in / Sign up

Export Citation Format

Share Document